These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35511392)

  • 41. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraoperative assessment of pancreatic neck margin at the time of pancreaticoduodenectomy increases likelihood of margin-negative resection in patients with pancreatic cancer.
    Dillhoff M; Yates R; Wall K; Muscarella P; Melvin WS; Ellison EC; Bloomston M
    J Gastrointest Surg; 2009 May; 13(5):825-30. PubMed ID: 19277793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upfront surgery.
    Li B; Guo S; Yin X; Ni C; Gao S; Li G; Ni C; Jiang H; Lau WY; Jin G
    Asian J Surg; 2023 Apr; 46(4):1541-1549. PubMed ID: 36376184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [R1 resection for pancreatic carcinoma].
    Weber GF; Kersting S; Haller F; Grützmann R
    Chirurg; 2017 Sep; 88(9):764-770. PubMed ID: 28653152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection.
    Dillon DL; Park JY; Mederos MA; Seo YJ; King J; Hines J; Donahue T; Girgis MD
    J Surg Oncol; 2024 Jul; 130(1):72-82. PubMed ID: 38726668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Raut CP; Tseng JF; Sun CC; Wang H; Wolff RA; Crane CH; Hwang R; Vauthey JN; Abdalla EK; Lee JE; Pisters PW; Evans DB
    Ann Surg; 2007 Jul; 246(1):52-60. PubMed ID: 17592291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.
    Teske C; Stimpel R; Distler M; Merkel S; Grützmann R; Bolm L; Wellner U; Keck T; Aust DE; Weitz J; Welsch T
    Langenbecks Arch Surg; 2021 Aug; 406(5):1481-1489. PubMed ID: 33712875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.
    Demir IE; Jäger C; Schlitter AM; Konukiewitz B; Stecher L; Schorn S; Tieftrunk E; Scheufele F; Calavrezos L; Schirren R; Esposito I; Weichert W; Friess H; Ceyhan GO
    Ann Surg; 2018 Dec; 268(6):1058-1068. PubMed ID: 28692477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
    Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
    World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
    Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
    Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal adenocarcinoma.
    Katou S; Wenning AS; Aeschbacher P; Morgul H; Becker F; Pascher A; Gloor B; Strücker B; Andreou A
    Surgery; 2023 Jul; 174(1):91-99. PubMed ID: 37121858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I.
    Vega EA; Kutlu OC; Salehi O; James D; Alarcon SV; Herrick B; Krishnan S; Kozyreva O; Conrad C
    J Gastrointest Surg; 2020 Oct; 24(10):2409-2415. PubMed ID: 32394126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intraoperative Positive Pancreatic Parenchymal Resection Margin: Is It a True Indication of Completion Total Pancreatectomy after Partial Pancreatectomy for Pancreatic Ductal Adenocarcinoma?
    Jung JH; Yoon SJ; Lee OJ; Shin SH; Heo JS; Han IW
    Curr Oncol; 2022 Jul; 29(8):5295-5305. PubMed ID: 36005158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact on Long-term Survival of a Standardized Histopathological Protocol on the R1 Incidence in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma.
    Moiş E; Graur F; Puia C; Vlad I; Moldovan S; Ursu CP; Nechita VI; Vălean D; Furcea L; Puia A; Zaharie F; Popa C; Bodea R; Iancu C; Rusu I; Hajjar NA
    Chirurgia (Bucur); 2024 Apr; 119(2):171-183. PubMed ID: 38743830
    [No Abstract]   [Full Text] [Related]  

  • 57. Neoadjuvant Treatment for Pancreatic Cancer.
    Raufi AG; Manji GA; Chabot JA; Bates SE
    Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study.
    Li Z; Zhuo Q; Li B; Liu M; Chen C; Shi Y; Xu W; Liu W; Ji S; Yu X; Xu X
    World J Surg Oncol; 2024 Jan; 22(1):1. PubMed ID: 38169384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.